LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

A global Europe – the role of transformative legislation for biotech. EuropaBio Nacional Associations Spanish Council Presidency Summit

16/10/2023

PRESS RELEASE

Brussels, 16 October 2023 – The Spanish Presidency of the Council of the European Union has established several priorities for the second half of 2023 to ensure Europe's global position and strategic autonomy, including promoting the transition towards a more sustainable agri-food production model and strengthening EU's health autonomy through European-based innovation.

EuropaBio National Associations Council, with the support of AseBio - the Spanish Association of Biotechnology Companies, shares their recommendations, based on their Presidency event, for two fundamental policy proposals - the revision of the general pharmaceutical legislation and the proposal for a regulation on plants obtained by certain New Genomic Techniques.

On the revision of the general pharmaceutical legislation, national associations emphasize the importance of an adequate and balanced incentives framework and recommend that any conceptualization of "unmet medical need" is non-legislative and agreed upon in a multi-stakeholder patient-centric approach. Biotechnology developers also stress the need to boost the clinical research environment, improving the numbers of clinical trials in Europe and building on the Cross-Border Healthcare Directive achievements to ensure early patient access to innovative therapies.

For the use of new genomic techniques for plants, national associations stress the need to ensure regulatory certainty for product authorization. It is crucial to accelerate the overall revision of the GMO framework across sectors beyond plants to align with existing scientific advances and have a proposal for additional policy actions on genetically modified microorganisms. Claire Skentelbery, Director General of EuropaBio commented:

“It is now more important than ever to guarantee that Europe can achieve strategic autonomy and robust supply chains. In a geopolitically unstable environment, Europe must ensure it can innovate and create new alternatives for the agri-food sector and the next generation of therapies for European patients. EuropaBio National Associations remain committed to working with our partners during the remainder of the Spanish Council Presidency while it prepares the work for the upcoming Belgium Presidency.”

Press Release Spanish Presidency Summit 2023


Download

Event Report-EuropaBio National Associations Summit 2023 Spanish Council Presidency


Download

Share
Francesca Degli Agostini
Francesca Degli Agostini

Related posts

10/06/2025

EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union


Read more
10/06/2025

The EU economic and scientific future starts with the EU Biotech Act


Read more
05/06/2025

The GPL must include biotech & life science to unleash EU innovation


Read more

Important links

  • EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union
  • The EU economic and scientific future starts with the EU Biotech Act

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.